Cardiotoxicity is a common side effect induced by cancer therapies, which increases the risk
of long-term morbidity and mortality in cancer survivors. To date, the mechanism leading to …

Cancer is one of the diseases, which it is not still completely curable; the existing treatments
are associated with many complications, that double its complexity. One of the causes of …

Cardiovascular safety assessment is vital for drug development, yet human cardiovascular
cell models are lacking. In vitro mass-generated human pluripotent stem cell (hPSC)-derived …

Abstract Purpose of Review This review explores the cardiovascular toxicity associated with
cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It …

Trastuzumab is used to treat breast cancer patients overexpressing human epidermal
growth factor receptor 2, but resistance and toxicity limit its uses, leading to attention to …

Anthracyclines are widely used in the treatment of many solid cancers, but their efficacy is
limited by cardiotoxicity. As the number of pediatric cancer survivors continues to rise, there …

The advent of induced pluripotent stem cells (iPSCs) and identification of transcription
factors for cardiac reprogramming have raised hope to cure heart disease, the leading …

Cancer therapies with anthracyclines have been shown to induce cardiovascular
complications. The aims of this study were to establish an in vitro induced pluripotent stem …

Significant advances in chemotherapy drugs have reduced mortality in patients with
malignant tumors. However, chemotherapy-related cardiotoxicity increases the morbidity …

Somatic cells such as skin fibroblasts, umbilical cord blood, peripheral blood, urinary
epithelial cells, etc., are transformed into induced pluripotent stem cells (iPSCs) by …